• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.

作者信息

Nakamura Hideta, Miyagi Kazuya, Otsuki Mariko, Higure Yuuri, Nishiyama Naoya, Kinjo Takeshi, Nakamatsu Masashi, Haranaga Shusaku, Tateyama Masao, Fujita Jiro

机构信息

Department of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus, Graduate School of Medicine, 207 Uehara, Nishihara-cho, Okinawa 903-0215, Japan.

Department of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus, Graduate School of Medicine, 207 Uehara, Nishihara-cho, Okinawa 903-0215, Japan.

出版信息

Respir Investig. 2020 Nov;58(6):510-512. doi: 10.1016/j.resinv.2020.09.006. Epub 2020 Oct 7.

DOI:10.1016/j.resinv.2020.09.006
PMID:33067149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7539801/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da0/7539801/ddcf2029c0d4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da0/7539801/ddcf2029c0d4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7da0/7539801/ddcf2029c0d4/gr1_lrg.jpg

相似文献

1
Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.白细胞介素6抑制剂托珠单抗在日本新冠病毒相关急性呼吸窘迫综合征所致细胞因子释放综合征患者中的应用：病例系列
Respir Investig. 2020 Nov;58(6):510-512. doi: 10.1016/j.resinv.2020.09.006. Epub 2020 Oct 7.
2
A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.托珠单抗治疗 COVID-19 急性呼吸窘迫综合征的全面综述
J Clin Pharmacol. 2020 Sep;60(9):1131-1146. doi: 10.1002/jcph.1693. Epub 2020 Jul 27.
3
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.托珠单抗治疗 COVID-19 诱导的细胞因子风暴和急性呼吸窘迫综合征：来自宾夕法尼亚州西部农村一级创伤中心的病例系列。
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211019557. doi: 10.1177/23247096211019557.
4
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.高剂量皮下注射阿那白滞素治疗重症 COVID-19 患者细胞因子风暴综合征继发急性呼吸窘迫综合征。
J Autoimmun. 2020 Dec;115:102537. doi: 10.1016/j.jaut.2020.102537. Epub 2020 Aug 20.
5
Repurposed Tocilizumab in Patients with Severe COVID-19.托珠单抗在重症 COVID-19 患者中的再利用。
J Immunol. 2021 Feb 1;206(3):599-606. doi: 10.4049/jimmunol.2000981. Epub 2020 Dec 9.
6
The shortcomings of tocilizumab in COVID-19.托珠单抗在治疗新型冠状病毒肺炎中的不足之处。
Infez Med. 2020 Dec 1;28(4):465-468.
7
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.白细胞介素-6 抑制剂在治疗 COVID-19 相关细胞因子释放综合征中的作用。
Int J Med Sci. 2021 Jan 21;18(6):1356-1362. doi: 10.7150/ijms.53564. eCollection 2021.
8
Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19.使用托珠单抗治疗印度尼西亚重症 COVID-19 患者的经验。
Cytokine. 2021 Feb;138:155393. doi: 10.1016/j.cyto.2020.155393. Epub 2020 Dec 14.
9
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.静脉注射托珠单抗治疗 COVID-19 相关炎症综合征的有效性和安全性：Covizumab-6 观察性队列研究。
Clin Immunol. 2021 Feb;223:108631. doi: 10.1016/j.clim.2020.108631. Epub 2020 Nov 12.
10
Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.白细胞介素-6阻断治疗用于一名慢性髓性白血病控制不佳患者的新型冠状病毒肺炎相关细胞因子释放综合征
Br J Haematol. 2020 Aug;190(3):e128-e130. doi: 10.1111/bjh.16901. Epub 2020 Jun 26.